This article is more than 5 years old. Information may no longer be current.

Bone graft technology receives patent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Patent and Trademark Office issued a fundamental patent for ISTO Technologies’ InQu Bone Graft Extender and Substitute.

Used primarily as an osteobiologic product in spinal fusion applications, InQu is a platform technology for tissue regeneration. InQu is manufactured and marketed as granules, pastes, putties and strips. According to a company press release, it has been used in more than 17,000 orthopedic and spinal procedures since its launch in 2008 and has received 510(k) clearances as a bone graft extender and substitute.

“This U.S. patent further protects and solidifies our leadership position in leveraging the properties of hyaluronic acid for orthopedic biologic applications,” Mitchell Seyedin, PhD, president and chief executive officer of ISTO Technologies, stated in the release.